Vericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss Ratings

Key Points

• Vericel's stock has been given a "Sell (D+)" rating by Weiss Ratings, indicating caution for potential investors.
• BTIG Research recently downgraded Vericel from a "buy" to a "neutral" rating, contributing to a mixed analyst outlook on the stock.
• The company's stock price reached $34.13 recently, with a market capitalization of $1.72 billion and a 52-week high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report)'s stock had its "sell (d+)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

VCEL has been the subject of a number of other reports. BTIG Research lowered shares of Vericel from a "buy" rating to a "neutral" rating in a research report on Wednesday, September 17th. Stephens restated an "overweight" rating and issued a $67.00 price objective on shares of Vericel in a research report on Monday, June 16th. Finally, Canaccord Genuity Group cut their price objective on shares of Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a research report on Friday, August 1st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vericel currently has an average rating of "Moderate Buy" and an average target price of $60.40.

Vericel Price Performance

NASDAQ:VCEL traded up $1.02 on Wednesday, reaching $34.13. 384,503 shares of the company's stock were exchanged, compared to its average volume of 914,508. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of 284.44 and a beta of 1.39. Vericel has a 52 week low of $29.24 and a 52 week high of $63.00. The stock has a fifty day simple moving average of $34.04 and a 200-day simple moving average of $38.87.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. The firm had revenue of $63.24 million during the quarter, compared to analyst estimates of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The company's quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) earnings per share. As a group, sell-side analysts predict that Vericel will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Corient Private Wealth LLC purchased a new position in shares of Vericel during the second quarter worth approximately $282,000. Valeo Financial Advisors LLC raised its stake in shares of Vericel by 11.1% during the second quarter. Valeo Financial Advisors LLC now owns 10,300 shares of the biotechnology company's stock worth $438,000 after acquiring an additional 1,026 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 353 shares in the last quarter. Public Sector Pension Investment Board raised its stake in shares of Vericel by 9.7% during the second quarter. Public Sector Pension Investment Board now owns 171,642 shares of the biotechnology company's stock worth $7,303,000 after acquiring an additional 15,153 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Vericel by 7,627.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,791 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 4,729 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.